Continuous Manufacturing in Canada: What ICH Q13 Means for Drug Sponsors Under Health Canada's GMP Framework

The first question Health Canada reviewers tend to ask when they see a continuous manufacturing (CM) dossier is whether you’ve defined your batch. Not the control strategy, not the PAT architecture — the batch. It sounds almost quaint given the sophistication of the technology involved, but that single question reveals how much a regulatory framework built around discrete batch processing still has to adapt to processes where drug substance flows continuously from raw material to finished product without interruption.

ICH Q13, finalized at Step 4 in November 2022, was supposed to provide the roadmap. And it has, substantially — but implementation across ICH member agencies remains uneven, and Health Canada’s path has nuances that Canadian drug sponsors need to understand before committing to continuous manufacturing for a new or existing product.

What ICH Q13 Requires and How It Maps to Canada’s GMP Framework

ICH Q13, titled “Continuous Manufacturing of Drug Substances and Drug Products,” covers two broad system types: integrated continuous manufacturing (ICM), where unit operations run without intermediate storage or testing between steps, and semi-continuous processes, where some operations are continuous and others retain a discrete batch character.

The guideline’s core regulatory requirements centre on four elements. First, a control strategy that provides real-time assurance of product quality, rather than depending solely on end-product testing. Second, a clear batch definition — typically expressed as material produced over a specified time interval or at a defined production rate — that anchors all batch records, in-process controls, and release specifications. Third, process analytical technology (PAT) that generates the real-time data the control strategy depends on to function. And fourth, provisions for real-time release testing (RTRT), which can replace conventional end-product testing when the control strategy provides equivalent assurance of quality.

Health Canada is an ICH founding regulatory member and has committed to implementing ICH Q13 into Canadian practice. As of mid-2026, Health Canada’s pre-submission feedback and regulatory communications reflect alignment with ICH Q13 principles, but Health Canada has not yet published a standalone CM-specific guidance document comparable to what the FDA’s Office of Pharmaceutical Quality has produced. For Canadian sponsors, this matters. You’re largely working from the ICH Q13 text itself, interpreted against Health Canada’s existing GMP guidelines — primarily GUI-0001, which governs finished pharmaceutical products manufactured or imported into Canada.

The gap between “ICH alignment” and “published guidance” is exactly where sponsors get surprised. Assumptions that work cleanly in an FDA submission don’t always translate.

Where Canada’s GMP Requirements Create Friction for CM

Canada’s pharmaceutical GMP requirements flow from Part C, Division 2 of the Food and Drug Regulations, supported by Health Canada’s guidance documents. This regulatory architecture was written with traditional batch manufacturing in mind. The friction with CM isn’t incompatibility — it’s the need to interpret existing requirements through a fundamentally different process lens.

Batch records. Health Canada requires complete batch production records. In an ICM process, a “batch” might be defined as 8 hours of production at a specified throughput rate, or a defined mass of drug product, rather than a single discrete granulation or tableting run. Your batch definition needs to be explicit in your quality system, and your batch record infrastructure — whether paper-based or electronic — must capture continuous process data streams in a way that is attributable, legible, contemporaneous, and complete. Health Canada GMP inspectors reviewing CM operations have flagged batch record completeness as an observation when PAT instrument data streams aren’t fully integrated into the master batch record system.

Equipment qualification. GMP requirements call for equipment to be suitable for its intended use and appropriately qualified. In CM, this means qualifying the integrated manufacturing system — not just individual unit operations — and demonstrating consistent performance across the defined batch duration. Qualification protocols that treat the blender, roller compactor, and tablet press as independent systems without characterizing their interdependencies will not adequately address a Health Canada inspection of an ICM line.

Change control. Any modification to a CM process — an adjustment to residence time distribution, recalibration of a PAT measurement system, a raw material attribute specification change — can propagate effects through the entire control strategy in ways that rarely arise in conventional batch processing. GUI-0001 requires documented change control, but the risk classification of changes in a CM context often warrants higher categorization than the same change would receive in batch operations. We see sponsors consistently underestimate this burden during initial CM implementation planning.

One area worth particular attention: if your control strategy relies on RTRT to make real-time release decisions, the data system generating those decisions becomes a manufacturing-critical system, not simply a QC tool. That classification carries direct implications for software validation, audit trail requirements, and change control — obligations that span both GMP and Health Canada’s expectations for computerized systems in regulated manufacturing environments.

What Health Canada Reviewers Expect in CM Regulatory Submissions

For a New Drug Submission (NDS) or Abbreviated New Drug Submission (ANDS) incorporating CM, the chemistry, manufacturing, and controls (CMC) module carries most of the complexity. Health Canada reviewers work from ICH Q13 and the Common Technical Document (CTD) format, but they will look for CM-specific elements that go beyond a conventional batch CMC package.

The control strategy document. ICH Q13 elevates the control strategy from a CMC summary section to a detailed, standalone document. Reviewers expect it to identify all critical quality attributes (CQAs), link them explicitly to critical process parameters (CPPs) and material attributes, and explain how real-time monitoring ensures those CQAs remain within specification across the entire batch duration — including startup, steady-state, and shutdown phases. A control strategy document that reads like a conventional batch CMC summary will generate clarification requests.

Batch definition and scale justification. In CM, scale is typically expressed as production rate and duration rather than vessel size or batch mass. Regulatory submissions must clearly define the commercial batch definition and justify why development data — often generated at different throughput rates or durations — is predictive of commercial-scale performance. Health Canada reviewers have requested additional data packages when development batches were produced under conditions substantially different from the commercial proposal.

RTRT justification. Relying on RTRT to release product without conventional end-product testing requires a robust scientific argument: the mechanistic or statistical basis for the predictive relationship between real-time measurements and the quality attribute, the uncertainty bounds on that relationship, and explicit action plans for what happens when real-time data approaches or exceeds action limits mid-batch. “The PAT data correlates well with the assay result” is not an adequate regulatory justification.

One practical reality for Canadian sponsors: Health Canada’s review capacity for novel manufacturing technologies is more limited than the FDA’s Office of Pharmaceutical Quality (OPQ), which has reviewed and approved more than a dozen products manufactured using continuous or semi-continuous processes since 2015. Health Canada’s Pre-Submission Program — which allows sponsors to discuss complex submissions before filing — isn’t optional for a CM dossier. It’s the mechanism for confirming reviewer expectations before you’ve committed to a CMC package structure you may need to substantially revise.

What Canadian Drug Sponsors Should Be Doing Now

Continuous manufacturing isn’t an emerging curiosity. It’s an established commercial technology for solid oral dosage forms, with several major global manufacturers having standardized on CM platforms for new product launches. Canadian sponsors — whether you’re a domestic manufacturer, a CRO supporting a sponsor’s filing, or a CMO building technical capacity — need to be positioning for this now.

Audit your quality system against ICH Q13, not just GUI-0001. The differences are real. Equipment qualification protocols, batch record systems, change control procedures, and RTRT validation frameworks all need to be evaluated against CM-specific expectations, and gaps identified and closed before you’re assembling a submission package.

Request a pre-submission meeting and be specific. State clearly that your submission involves continuous manufacturing and identify the precise questions you need answered — particularly around batch definition, RTRT scope, and control strategy documentation format. A single well-prepared pre-submission meeting can eliminate months of back-and-forth during review.

Build your control strategy as an operational document. In continuous manufacturing, the control strategy is the quality system. Manufacturing teams, QA teams, and regulatory teams all need to work from it — and your change control process needs to explicitly address how changes to process parameters, PAT instruments, or raw material specifications trigger control strategy revisions. Building it as a CMC-only document and retrofitting it for operations is a path that creates problems quickly.

Budget for longer timelines. CM submissions typically generate more clarification requests than conventional CMC packages, regardless of regulatory jurisdiction. And don’t assume an approved FDA submission automatically supports a Health Canada filing without CM-specific supplementary documentation. The two agencies align on ICH Q13 principles, but their documentation expectations have differences that matter in practice — differences that can turn a 12-month review timeline into an 18-month one.

Canada’s regulatory path for continuous manufacturing is functional but still maturing. The sponsors who engage with that reality directly — rather than treating a Health Canada CM submission as a straightforward adaptation of their FDA package — are the ones who avoid the surprises.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Pharmaceutical Analytical Testing and Method Validation in the US — How US FDA expectations for PAT and analytical method validation compare to the Health Canada framework, with ISO 17025-accredited testing support.
• EU GMP and Advanced Manufacturing Regulatory Requirements — European regulatory expectations for novel manufacturing approaches, including how EMA’s scientific advice process handles continuous manufacturing submissions.